Srinivas K. Tantravahi
( out of 102 reviews )

Srinivas K. Tantravahi, MBBS, MRCP(UK)

Languages spoken: English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
2000 Circle of Hope
Salt Lake City , UT 84112
801-585-2626
Get Directions

  • Dr. Srinivas Tantravahi is an Associate Professor specializing in Hematology and Hematologic Malignancies within the Division of Hematology at the Huntsman Cancer Institute, University of Utah. Board certified in Hematology and Medical Oncology, Dr. Tantravahi is an expert in the management of leukemias, myeloproliferative neoplasms, bone marrow failure, and genetic predisposition to related conditions.

    After completing his Internal Medicine residency and Hematology and Oncology fellowship training at the University of Utah School of Medicine, Dr. Tantravahi joined the University of Utah faculty in 2015. He actively engages in pioneering clinical trials, investigating innovative therapeutic strategies for myeloproliferative neoplasms, chronic myeloid leukemia, acute myeloid leukemia, and acute lymphoblastic leukemia. Dr. Tantravahi is a member of the American Society of Hematology, Society of Hematologic Oncology, and American Society of Clinical Oncology.

    Dr. Tantravahi's clinical and research focus extends to the diagnosis and treatment of telomere biology disorders, with a particular emphasis on unraveling the genetic mechanisms underlying these disorders and various germline predispositions to bone marrow failure and leukemias.

    To schedule an appointment:

    New MDS/AML Patients: 801-587-4630. New MPN Patients: 801-646-4122. Returning patients: 801-585-2626 or schedule through MyChart.

    For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or your family member, please feel free to contact our Clinical Care Specialist at (801) 587-4630.

    Specialties

    Board Certification

    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)
    Medical Council of India
    American Board of Internal Medicine

    Patient Rating

    4.9 /5
    ( out of 102 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    HUNTSMAN CANCER CENTER

    As stated previously, Dr. Tantravahi talks with you, not at you. He discusses medical problems in easy terms to understand and explains why something is best for you, the patient. Also, I have great respect for his knowledge in the field of hematology. He listens carefully to anything you want to discuss.

    HUNTSMAN CANCER CENTER

    Enjoyed my visit. My questions were answered and I feel confident where my treatment is geaded

    HUNTSMAN CANCER CENTER

    I felt like I was interrupting something and really didn't seem to be the focus of the doctor during my visit.

    SUGAR HOUSE HEALTH CENTER

    Dr. Tantravahi treated me with respect and included me in the decision making of my care. He is an outstanding doctor.

    HUNTSMAN CANCER CENTER

    Dr. T explained his concerns regarding my treatment as well as explained everything to my satisfaction.

    HUNTSMAN CANCER CENTER

    Very good experience.

    HUNTSMAN CANCER CENTER

    Dr T makes me feel so much better re my health concerns. Like speaking to a family member. Dr T is super GREAT!

    SUGAR HOUSE HEALTH CENTER

    All Excellent

    SUGAR HOUSE HEALTH CENTER

    Dr. Tantravahi explained everything easily and showed concern for me during my appointment. His bedside manner was great.

  • Dr. Srinivas Tantravahi is an Associate Professor specializing in Hematology and Hematologic Malignancies within the Division of Hematology at the Huntsman Cancer Institute, University of Utah. Board certified in Hematology and Medical Oncology, Dr. Tantravahi is an expert in the management of leukemias, myeloproliferative neoplasms, bone marrow failure, and genetic predisposition to related conditions.

    After completing his Internal Medicine residency and Hematology and Oncology fellowship training at the University of Utah School of Medicine, Dr. Tantravahi joined the University of Utah faculty in 2015. He actively engages in pioneering clinical trials, investigating innovative therapeutic strategies for myeloproliferative neoplasms, chronic myeloid leukemia, acute myeloid leukemia, and acute lymphoblastic leukemia. Dr. Tantravahi is a member of the American Society of Hematology, Society of Hematologic Oncology, and American Society of Clinical Oncology.

    Dr. Tantravahi's clinical and research focus extends to the diagnosis and treatment of telomere biology disorders, with a particular emphasis on unraveling the genetic mechanisms underlying these disorders and various germline predispositions to bone marrow failure and leukemias.

    To schedule an appointment:

    New MDS/AML Patients: 801-587-4630. New MPN Patients: 801-646-4122. Returning patients: 801-585-2626 or schedule through MyChart.

    For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or your family member, please feel free to contact our Clinical Care Specialist at (801) 587-4630.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Associate Professor (Clinical)
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)
    Medical Council of India
    American Board of Internal Medicine

    Education history

    Professional Medical Medicine - Guntur Medical College M.B.B.S.
    Residency Internal Medicine - George Elliot Hospital Senior House Officer
    Residency Internal Medicine - Macclesfield District General Hospital Senior House Officer
    Residency Internal Medicine - Rotherham District General Hospital Senior House Officer
    Residency Internal Medicine - Sheffield Teaching Hospitals Senior House Officer
    Residency Internal Medicine - Barnsley District General Hospital Senior House Officer
    Residency Internal Medicine - University of Utah Resident
    Fellowship Hematology & Oncology - University of Utah Fellow
    Fellowship Advanced Hematology & Oncology - University of Utah Fellow

    Selected Publications

    Journal Article

    1. Khorashad JS, Eiring AM, Mason CC, Gantz KC, Bowler AD, Redwine HM, Yu F, Kraft IL, Pomicter AD, Reynolds KR, Iovino AJ, Zabriskie MS, Heaton WL, Tantravahi SK, Kauffman M, Shacham S, Chenchik A, Bonneau K, Ullman KS, O'Hare T, Deininger M (2015). shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance. Blood, 125(11), 1772-81. (Read full publication)
    2. Willis C, Menon J, Unni S, Au T, Yoo M, Biskupiak J, Brixner D, Ndife B, Joseph G, Bonifacio G, Stein E, Tantravahi S, Shami PJ, Kovacsovics T, Stenehjem (2019). Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center. Leukemia research, 87, 106262. (Read full publication)
    3. Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Moriggl R, Wilson DJ, Baron R, O'Hare T, Gunning PT, Deininger M (2015). Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia, 29(3), 586-597. (Read full publication)
    4. Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, Pomicter AD, Reynolds KR, Eiring AM, Kronenberg Z, Sherman RL, Tyner JW, Dalley BK, Dao KH, Yandell M, Druker BJ, Gotlib J, O'Hare T, Deininger M (2016). Age-related mutations and chronic myelomonocytic leukemia. Leukemia, 30(4), 906-13. (Read full publication)
    5. Patel AB, Pomicter AD, Yan D, Eiring AM, Antelope O, Schumacher JA, Kelley TW, Tantravahi SK, Kovacsovics TJ, Shami PJ, O'Hare T, Deininger M (2020). Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. Leukemia, 34(11), 2981-2991. (Read full publication)
    6. Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, Wang Q, Than H, Patel AB, Heaton WL, Eiring AM, Clair PM, Gantz KC, Redwine HM, Swierczek SI, Halverson BJ, Baloglu E, Shacham S, Khorashad JS, Kelley TW, Salama ME, Miles RR, Boucher KM, Prchal JT, O'Hare T, Deininger M (2019). Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis. Clinical cancer research, 25(7), 2323-2335. (Read full publication)
    7. Walker BS, Schmidt RL, Tantravahi S, Kim K, Hanson K (2019). Cost-effectiveness of antifungal prophylaxis, preemptive therapy, or empiric treatment following allogeneic hematopoietic stem cell transplant. Transplant infectious disease, 21(5), e13148. (Read full publication)
    8. Bailey EB, Tantravahi SK, Poole A, Agarwal AM, Straubhar AM, Batten JA, Patel SB, Wells CE, Stenehjem DD, Agarwal (2015). Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. Clinical genitourinary cancer, 13(3), e131-7. (Read full publication)
    9. Patel SB, Stenehjem DD, Gill DM, Tantravahi SK, Agarwal AM, Hsu J, Vuong W, Pal SK, Agarwal (2016). Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies. Clinical genitourinary cancer, 14(2), 153-9. (Read full publication)
    10. Kim K, McMillin GA, Bernard PS, Tantravahi S, Walker BS, Schmidt R (2019). Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia. PloS one, 14(12), e0226552. (Read full publication)
    11. Tantravahi SK, Albertson D, Agarwal AM, Ravulapati S, Poole A, Patel SB, Hawatmeh JS, Straubhar AM, Liu T, Stenehjem DD, Agarwal (2015). Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. Journal of oncology, 2015, 181926. (Read full publication)
    12. Franzini A, Pomicter AD, Yan D, Khorashad JS, Tantravahi SK, Than H, Ahmann JM, O'Hare T, Deininger M (2019). The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations. Blood advances, 3(20), 2949-2961. (Read full publication)
    13. Li P, Venkatachalam S, Ospina Cordona D, Wilson L, Kovacsovics T, Moser KA, Miles RR, Beck DB, George T, Tantravahi S (2022). A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm. Blood advances, 6(2), 405-409. (Read full publication)
    14. Go RS, Jacobsen E, Baiocchi R, Buhtoiarov I, Butler EB, Campbell PK, Coulter DW, Diamond E, Flagg A, Goodman AM, Goyal G, Gratzinger D, Hendrie PC, Higman M, Hogarty MD, Janku F, Karmali R, Morgan D, Raldow AC, Stefanovic A, Tantravahi SK, Walkovich K, Zhang L, Bergman MA, Darlow S (2021). Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 19(11), 1277-1303. (Read full publication)
    15. Yang F, Long N, Anekpuritanang T, Bottomly D, Savage JC, Lee T, Solis-Ruiz JM, Borate U, Wilmot B, Tognon CE, Bock AM, Pollyea DA, Radhakrishnan SM, Radhakrishnan S, Patel PA, Collins RH, Tantravahi SK, Deininger MW, Fan G, Druker BJ, Shinde U, Tyner JW, Press RD, McWeeney SK, Agarwal (2021). Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult AML patients. Blood, 139(8), 1208-1221. (Read full publication)
    16. Pemmaraju N, Garcia JS, Potluri J, Harb JG, Sun Y, Jung P, Qin QQ, Tantravahi SK, Verstovsek S, Harrison (2022). Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study. The Lancet. Haematology, 9(6), e434-e444. (Read full publication)
    17. Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, Mohyuddin GR, Sborov D (2023). Impact of academic medical center access on outcomes in multiple myeloma. American journal of hematology, 98(1), 41-48. (Read full publication)
    18. Babushok DV, DeZern AE, de Castro C, Rogers ZR, Beenhouwer D, Broder MS, Fanning S, Gibbs SN, Hanna R, Maciejewski JP, Scott BL, Tantravahi SK, Wlodarski MW, Yermilov I, Patel B (2024). Modified Delphi Panel Consensus Recommendations for Management of Severe Aplastic Anemia. Blood advances, (Read full publication)
    19. Vardell VA, Ose J, Rets AV, Tantravahi SK, Patel A (2024). Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloid Leukemia: A National Analysis. Clinical lymphoma, myeloma & leukemia, 24(12), 843-851. (Read full publication)
    20. Cortes JE, Kim DW, Saikia T, Khattry N, Rathnam K, Alvarado Y, Hannah G, Tantravahi SK, Apperley JF, Charbonnier A, García-Gutiérrez V, Lucchesi A, Dima D, Illés Á, Popov VM, Abruzzese E, Nag A, Apte S, Badar T, Yao SL, Saxena U, Sreenivasan J, Inamdar S, Chimote G, Nicolini F (2025). Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial. The Lancet. Haematology, 12(3), e201-e213. (Read full publication)
    21. Li P, Alnoor FNU, Xie W, Williams M, Feusier J, Ding Y, Zhao X, Zheng G, Zhao C, Zieske AW, Zu Y, Raess PW, Tantravahi S, Osman A, Patel AB, Tashi T, Patel JL, Matynia AP, Menon MP, Miles RR, Jacobsen JR, George TI, Sborov DW, Szankasi P, Rindler P, Close D, Ohgami R (2025). Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS. Leukemia, 39(1), 248-256. (Read full publication)
    22. Berman E, Shah NP, Deninger M, Altman JK, Amaya M, Begna K, Bhatia R, Chan O, Collins R, Curtin P, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore J, Oehler V, Pratz K, Pusic I, Rose M, Shomali W, Smith BD, Styler M, Sweet K, Talpaz M, Tanaka T, Tantravahi S, Tsai S, Vaughn J, Welborn J, Yang D, Mauro M, Cortes J, Radich J, Druker (2024). CML and the WHO: Why?. Journal of clinical oncology, 42(9), 984-986. (Read full publication)
    23. Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, Chan O, Clements J, Collins RH, Curtin PT, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore JO, Oehler V, Pratz K, Pusic I, Rose MG, Shomali W, Smith BD, Styler M, Talpaz M, Tanaka TN, Tantravahi S, Thompson J, Tsai S, Vaughn J, Welborn J, Yang DT, Sundar H, Gregory (2024). Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 22(1), 43-69. (Read full publication)
    24. Tantravahi SK, Latremouille-Viau D, Desai R, Lee S, Paulose J, Geevarghese A, Guérin A, Seshasayee S, Chanpura M, Yen (2025). Real-World Prevalence and Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors in the US: A Retrospective Claims Database Analysis. Journal of health economics and outcomes research, 12(2), 66-74. (Read full publication)

    Book Chapter

    1. Tantravahi SK, Kovacsovics (2015). Myeloma. 83-102.
    2. Kollepara SLS, Tantravahi SK, Batten J, Agarwal (2014). Integrating emerging science into clinical practice: Targeting androgen signaling in Castration Resistant Metastatic Prostate Cancer.
    3. Tantravahi SK, Khorashad JS, Deininger M Genomic Landscape of myeloproliferative neoplasms.

    Letter

    1. Tantravahi SK, Szankasi P, Khorashad JS, Dao KH, Kovacsovics T, Kelley TW, Deininger M (2016). A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia. Leukemia & lymphoma, 57(10), 2441-4. (Read full publication)
    2. Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, Radhakrishnan SV, Chiron M, Miles R, Salama M, Kröger N, Luetkens (2020). In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. Leukemia, 34(1), 317-321. (Read full publication)
    3. Tantravahi SK, Huber BD, Vagher J, Maese L, Pomicter AD, Al-Sweel N, Asch JD, Toydemir RM, Hong B, Parker (2022). Genome-wide uniparental disomy as a mechanism of immune escape in acquired aplastic anaemia. British journal of haematology, 198(6), e78-e81. (Read full publication)

  • News & Podcasts

    Huntsman Cancer Institute News